Lombardy partners:
- Giovanni Montini, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, € 230.600,00
- Federica Collino, Università degli Studi di Milano, € 218.200,00
| Pathology of interest: | Idiopathic Nephrotic Syndrome |
| Area of research: | Rare diseases |
| Start date: | 11/10/2024 |
| End date: | 10/10/2027 |
| Funding: | € 448.800,00 |
| Project partners: | Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico (Italy) Università degli Studi di Milano (Italy) Center for Pediatrics and Adolescent Medicine- Heidelberg (Germany) University Hospital of Cologne (Germany) Medical University of Gdansk (Poland) Istanbul University (Türkiye) Clinic of Children’s Diseases Vilnius University (Lithuania) |
Idiopathic Nephrotic Syndrome is a rare disease of the kidneys, which typically affects children. For most affected children there is the need of a prolonged treatment with drugs reducing the activity of the immune system, also resulting in many side effects. Those patients, who do not respond to treatment, are at risk of kidney damage and of dialysis or kidney transplantation. It is currently impossible to predict the response to treatment, leading to unnecessary therapies with side effects as well as unclear prognosis in the affected children. The response of the idiopathic nephrotic syndrome to medications acting on the immune system explains its important role in the occurrence of the disease. With this study we aim to obtain predictors of the response to treatment right at the beginning of the disease, to adapt the therapy avoiding needless side effects. This will be done evaluating the blood and urine of affected children using state of the art molecular characterisation. We will evaluate the genetic predisposition; the cell trait changes and the presence of molecules in blood and urine that may affect the interaction between the immune system and the kidneys. We expect that the findings will improve treatment of children with idiopathic nephrotic syndrome and reduce the number of children suffering from unnecessary drugs related side effects.